Traws Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.82next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly3.1MTarget: Sufficient capital to fund operations and clinical milestones
Research and Development (R&D) Expenses Quarterly4.9MTarget: Controlled clinical development spending
Watch Items
- UK MHRA Regulatory Review of Tivoxavir Marboxil (TXM)Trigger: Negative review or deferral of Phase 2a human influenza challenge studyAction: Advance backup influenza antiviral compounds designed to address mutagenicity concerns while preserving pharmacokinetic profiles.
- FDA Clinical Hold on U.S. IND for Tivoxavir MarboxilTrigger: Resolution of toxicology and mutagenicity data package concernsAction: Engage with the FDA via Type B and Type D meetings to submit a comprehensive response and enable global clinical studies.
- PIPE Financing Milestone WarrantsTrigger: Invalidation of milestone-based warrants due to clinical trial deferralsAction: Manage cash runway (extending to Q1 2027) and seek alternative funding or strategic partnerships for paused oncology assets.
Research as of 20 Jun 2026